ASH presents Public Service Award to Sen. Sherrod Brown and Outstanding Service Award to Erik Fatemi

November 30, 2010

(WASHINGTON, November 30, 2010) - The American Society of Hematology (ASH) will honor Senator Sherrod Brown (D-OH) with the 2010 ASH Award for Public Service and Erik Fatemi, Majority Clerk for the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS), with the Award for Outstanding Service in recognition of their dedication to championing health care and research issues. These awards will be officially announced at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando, FL.

Sen. Brown is a long-time supporter of health care issues, including funding for the National Institutes of Health (NIH) and providing insurance coverage for clinical trials. He led the effort to include a provision requiring coverage of routine patient costs associated with clinical trial participation in the final health reform bill. Appointed to serve on the Senate Appropriations Committee early this year by the Senate Democratic leadership, he will play a prominent role in establishing annual funding levels for federal programs including the NIH.

Fatemi, a professional staff member of the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies since 2001, has tirelessly advocated for biomedical research over the last decade. He has worked on funding issues for the NIH and on policy related to overturning federal restrictions on embryonic stem cell research.

"The Society is very grateful to Sen. Brown and Mr. Fatemi for their efforts in support of Congressional policies that promote better care of patients," said Hal E. Broxmeyer, PhD, President of ASH and Distinguished Professor of Microbiology and Immunology at the Indiana University School of Medicine. "Without such dedicated champions of biomedical research funding, the scientific discoveries that lead to better treatments and cures for deadly diseases might not be possible."

The 2010 Public Service and Outstanding Service Awards will be formally announced prior to the Plenary Scientific Session on Sunday, December 5, at 1:30 p.m. in the Orange County Convention Center in Orlando.
Established in 1997, the ASH Public Service Award is given out annually to an elected public official who has demonstrated unparalleled leadership on issues of importance to hematology research and/or practice. The ASH Outstanding Service Award is presented each year to an individual in the private or public sector who has displayed effective "behind-the-scenes" leadership in areas relevant to the mission of the Society.

The American Society of Hematology ( is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers weekly, available in print and online at Follow ASH on Twitter at ASH_hematology.

American Society of Hematology

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to